通过筛选重组肽文库发现的高亲和力I型白细胞介素1受体拮抗剂。
High affinity type I interleukin 1 receptor antagonists discovered by screening recombinant peptide libraries.
作者信息
Yanofsky S D, Baldwin D N, Butler J H, Holden F R, Jacobs J W, Balasubramanian P, Chinn J P, Cwirla S E, Peters-Bhatt E, Whitehorn E A, Tate E H, Akeson A, Bowlin T L, Dower W J, Barrett R W
机构信息
Department of Molecular Pharmacology, Affymax Research Institute, Palo Alto, CA 94304, USA.
出版信息
Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):7381-6. doi: 10.1073/pnas.93.14.7381.
Abstract
Two families of peptides that specifically bind the extracellular domain of the human type I interleukin I (IL-1) receptor were identified from recombinant peptide display libraries. Peptides from one of these families blocked binding of IL-lalpha to the type I IL-1 receptor with IC50 values of 45-140 microM. Affinity-selective screening of variants of these peptides produced ligands of much higher affinity (IC50 approximately 2 nM). These peptides block IL-1-driven responses in human and monkey cells; they do not bind the human type II IL-1 receptor or the murine type I IL-1 receptor. This is the first example (that we know of) of a high affinity peptide that binds to a cytokine receptor and acts as a cytokine antagonist.
摘要
从重组肽展示文库中鉴定出了两类能特异性结合人I型白细胞介素I（IL-1）受体胞外域的肽。其中一个家族的肽可阻断IL-1α与I型IL-1受体的结合，IC50值为45 - 140微摩尔。对这些肽的变体进行亲和选择筛选，产生了亲和力高得多的配体（IC50约为2纳摩尔）。这些肽可阻断人和猴细胞中IL-1驱动的反应；它们不与人II型IL-1受体或鼠I型IL-1受体结合。这是（据我们所知）第一个与细胞因子受体结合并作为细胞因子拮抗剂的高亲和力肽的例子。
相似文献
1
High affinity type I interleukin 1 receptor antagonists discovered by screening recombinant peptide libraries.通过筛选重组肽文库发现的高亲和力I型白细胞介素1受体拮抗剂。
Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):7381-6. doi: 10.1073/pnas.93.14.7381.
2
Suramin blocks the binding of interleukin-1 to its receptor and neutralizes IL-1 biological activities.苏拉明可阻断白细胞介素-1与其受体的结合，并中和白细胞介素-1的生物学活性。
Int J Immunopharmacol. 1994 Nov;16(11):931-9. doi: 10.1016/0192-0561(94)00054-9.
3
ST2/T1 protein functionally binds to two secreted proteins from Balb/c 3T3 and human umbilical vein endothelial cells but does not bind interleukin 1.ST2/T1蛋白可与来自Balb/c 3T3细胞和人脐静脉内皮细胞的两种分泌蛋白发生功能性结合，但不与白细胞介素1结合。
J Biol Chem. 1995 Nov 17;270(46):27905-13. doi: 10.1074/jbc.270.46.27905.
4
Species-specific binding of IL-1, but not the IL-1 receptor antagonist, by fibroblasts.成纤维细胞对白细胞介素-1（IL-1）具有种属特异性结合，而对白细胞介素-1受体拮抗剂则没有。
Cytokine. 1994 Mar;6(2):154-61. doi: 10.1016/1043-4666(94)90037-x.
5
A synthetic peptide corresponding to 86-93 of the human type I IL-1 receptor binds human recombinant IL-1 (alpha and beta) and inhibits IL-1 actions in vitro and in vivo.一种与人I型白细胞介素-1受体86-93位相对应的合成肽，能结合人重组白细胞介素-1（α和β），并在体外和体内抑制白细胞介素-1的作用。
Biochem Biophys Res Commun. 1992 Oct 30;188(2):912-20. doi: 10.1016/0006-291x(92)91142-d.
6
Identification of potent human anti-IL-1RI antagonist antibodies.强效人抗白细胞介素-1受体拮抗剂抗体的鉴定
Protein Eng Des Sel. 2004 Jan;17(1):95-106. doi: 10.1093/protein/gzh012.
7
AF12198, a novel low molecular weight antagonist, selectively binds the human type I interleukin (IL)-1 receptor and blocks in vivo responses to IL-1.AF12198是一种新型低分子量拮抗剂，可选择性结合人I型白细胞介素（IL）-1受体，并阻断体内对IL-1的反应。
J Biol Chem. 1996 Nov 29;271(48):30517-23. doi: 10.1074/jbc.271.48.30517.
8
9
An antibody to a 17 amino acid synthetic peptide of the type I interleukin-1 receptor preferentially blocks interleukin-1 beta binding.一种针对I型白细胞介素-1受体的17个氨基酸合成肽的抗体可优先阻断白细胞介素-1β的结合。
J Interferon Cytokine Res. 1996 Dec;16(12):1079-88. doi: 10.1089/jir.1996.16.1079.
10
The search for inhibitors of interleukin-1 based on the sequence of interleukin-1 receptor antagonist.基于白细胞介素-1受体拮抗剂序列寻找白细胞介素-1抑制剂。
Biomed Pept Proteins Nucleic Acids. 1996;2(4):123-9.
引用本文的文献
1
Discovery of selective low molecular weight interleukin-36 receptor antagonists by encoded library technologies.通过编码文库技术发现选择性低分子量白细胞介素-36受体拮抗剂。
Nat Commun. 2025 Feb 15;16(1):1669. doi: 10.1038/s41467-025-56601-7.
2
Discovery of a selective and biologically active low-molecular weight antagonist of human interleukin-1β.发现一种选择性的、具有生物活性的人白细胞介素-1β小分子拮抗剂。
Nat Commun. 2023 Sep 7;14(1):5497. doi: 10.1038/s41467-023-41190-0.
3
Engineered Phage-Based Cancer Vaccines: Current Advances and Future Directions.工程化噬菌体癌症疫苗：当前进展与未来方向
Vaccines (Basel). 2023 Apr 29;11(5):919. doi: 10.3390/vaccines11050919.
4
Optimization of IL-1RA structure to achieve a smaller protein with a higher affinity to its receptor.优化 IL-1RA 结构，以获得一个更小的蛋白，使其对受体具有更高的亲和力。
Sci Rep. 2022 May 6;12(1):7483. doi: 10.1038/s41598-022-11100-3.
5
The Therapeutic Prospects of Targeting IL-1R1 for the Modulation of Neuroinflammation in Central Nervous System Disorders.靶向白细胞介素-1 受体 1 调节中枢神经系统疾病神经炎症的治疗前景。
Int J Mol Sci. 2022 Feb 2;23(3):1731. doi: 10.3390/ijms23031731.
6
Structural Basis of IL-1 Family Cytokine Signaling.白细胞介素-1 家族细胞因子信号的结构基础。
Front Immunol. 2019 Jun 20;10:1412. doi: 10.3389/fimmu.2019.01412. eCollection 2019.
7
Advancement and applications of peptide phage display technology in biomedical science.肽噬菌体展示技术在生物医学科学中的进展与应用
J Biomed Sci. 2016 Jan 19;23:8. doi: 10.1186/s12929-016-0223-x.
8
Identification of potential small molecule allosteric modulator sites on IL-1R1 ectodomain using accelerated conformational sampling method.使用加速构象采样方法鉴定白细胞介素-1受体1胞外域上潜在的小分子变构调节剂位点。
PLoS One. 2015 Feb 23;10(2):e0118671. doi: 10.1371/journal.pone.0118671. eCollection 2015.
9
The use of an IL-1 receptor antagonist peptide to control inflammation in the treatment of corneal limbal epithelial stem cell deficiency.使用白细胞介素-1受体拮抗剂肽来控制炎症，用于治疗角膜缘上皮干细胞缺乏症。
Biomed Res Int. 2015;2015:516318. doi: 10.1155/2015/516318. Epub 2015 Feb 1.
10
Synthetic phage for tissue regeneration.用于组织再生的合成噬菌体。
Mediators Inflamm. 2014;2014:192790. doi: 10.1155/2014/192790. Epub 2014 May 27.
本文引用的文献
1
A generic method for expression and use of "tagged" soluble versions of cell surface receptors.一种用于表达和使用细胞表面受体“标记”可溶性形式的通用方法。
Biotechnology (N Y). 1995 Nov;13(11):1215-9. doi: 10.1038/nbt1195-1215.
2
Modalities for reducing interleukin 1 activity in disease.降低疾病中白细胞介素1活性的方法。
Immunol Today. 1993 Jun;14(6):260-4. doi: 10.1016/0167-5699(93)90042-J.
3
Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4.白细胞介素-1Ⅱ型受体：一种受白细胞介素-4调节的白细胞介素-1诱饵靶点。
Science. 1993 Jul 23;261(5120):472-5. doi: 10.1126/science.8332913.
4
Interleukin 1 signaling occurs exclusively via the type I receptor.白细胞介素1信号传导仅通过I型受体发生。
Proc Natl Acad Sci U S A. 1993 Jul 1;90(13):6155-9. doi: 10.1073/pnas.90.13.6155.
5
Applications of combinatorial technologies to drug discovery. 1. Background and peptide combinatorial libraries.组合技术在药物发现中的应用。1. 背景与肽组合文库
J Med Chem. 1994 Apr 29;37(9):1233-51. doi: 10.1021/jm00035a001.
6
IL-1 inducible genes in human umbilical vein endothelial cells.人脐静脉内皮细胞中的白细胞介素-1诱导基因
Eur Heart J. 1993 Dec;14 Suppl K:78-81.
7
Mapping receptor binding sites in interleukin (IL)-1 receptor antagonist and IL-1 beta by site-directed mutagenesis. Identification of a single site in IL-1ra and two sites in IL-1 beta.通过定点诱变绘制白细胞介素（IL）-1受体拮抗剂和IL-1β中的受体结合位点。确定IL-1ra中的一个位点和IL-1β中的两个位点。
J Biol Chem. 1995 May 12;270(19):11477-83. doi: 10.1074/jbc.270.19.11477.
8
Crystal structure of a complex between interferon-gamma and its soluble high-affinity receptor.干扰素-γ与其可溶性高亲和力受体复合物的晶体结构
Nature. 1995 Jul 20;376(6537):230-5. doi: 10.1038/376230a0.
9
Interleukin-I antagonists.白细胞介素-1拮抗剂
Ther Immunol. 1994 Apr;1(2):113-22.
10
Peptides which bind to E-selectin and block neutrophil adhesion.与E-选择素结合并阻断中性粒细胞黏附的肽。
J Biol Chem. 1995 Sep 8;270(36):21129-36. doi: 10.1074/jbc.270.36.21129.
Zotero 插件